EFTReFFECTOR Therapeutics, Inc.

About eFFECTOR Therapeutics, Inc. (EFTR)

eFFECTOR Therapeutics, Inc. (EFTR) is a Biotechnology company headquartered in Foxboro, MA, United States whose shares trade over-the-counter on the Expert Market tier.

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E.

EFTR key facts

Ticker symbol

EFTR

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Foxboro, MA, United States

Country of incorporation

US

Estimated market cap

$940.882 (as of Apr 15, 2025)

Shares outstanding

4,704,409

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with E